Close Menu

NEW YORK – Scandinavian private equity firm Summa Equity said Wednesday that it has acquired functional proteomics firm Sengenics.

Founded in 2008, Sengenics produces full-length folded protein arrays using its KREX protein folding technology. Currently, the company is focused on using the technology to discover autoantibody signatures that could be useful for detecting and managing autoimmune and infectious diseases and cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.